NanoVibronix (ENvue Medical) Files 8-K with Corporate Updates
Ticker: FEED · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1326706
| Field | Detail |
|---|---|
| Company | Nanovibronix, Inc. (FEED) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing, name-change
TL;DR
ENvue Medical (formerly NanoVibronix) filed an 8-K on Dec 8, 2025, with corporate updates and financial filings.
AI Summary
NanoVibronix, Inc. (now ENvue Medical, Inc.) filed an 8-K on December 12, 2025, reporting events as of December 8, 2025. The filing indicates amendments to articles of incorporation or bylaws, a Regulation FD disclosure, and the filing of financial statements and exhibits. The company's principal executive address is listed as 969 Pruitt Ave, Tyler, Texas.
Why It Matters
This 8-K filing signals potential corporate restructuring or significant disclosures for NanoVibronix, now operating as ENvue Medical, Inc., which could impact investors' understanding of the company's current status and future direction.
Risk Assessment
Risk Level: low — The filing is a routine corporate update and does not appear to contain any immediately adverse financial or operational news.
Key Players & Entities
- NanoVibronix, Inc. (company) — Former company name
- ENvue Medical, Inc. (company) — Current company name
- December 8, 2025 (date) — Date of earliest event reported
- December 12, 2025 (date) — Filing date
- 969 Pruitt Ave, Tyler, Texas 77569 (address) — Principal executive address
FAQ
What specific amendments were made to the articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the excerpt.
What is the nature of the Regulation FD disclosure?
The filing states there is a Regulation FD disclosure, but the content of this disclosure is not detailed in the provided text.
What financial statements and exhibits are being filed?
The filing confirms that financial statements and exhibits are being filed, but their specific contents are not listed in this excerpt.
When did NanoVibronix, Inc. change its name to ENvue Medical, Inc.?
The filing indicates a name change from Nano Vibronix, Inc. to NanoVibronix, Inc. on December 6, 2011, and a prior name change from FORMER COMPANY to Nano Vibronix Inc on May 10, 2005. The exact date of the change to ENvue Medical, Inc. is not explicitly stated but implied by the filing.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 3842, which corresponds to Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Filing Stats: 785 words · 3 min read · ~3 pages · Grade level 10.3 · Accepted 2025-12-12 09:06:28
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share FEED Nasdaq Capital Marke
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex3-1.htm (EX-3.1) — 15KB
- ex99-1.htm (EX-99.1) — 14KB
- 0001493152-25-027380.txt ( ) — 241KB
- feed-20251208.xsd (EX-101.SCH) — 3KB
- feed-20251208_lab.xml (EX-101.LAB) — 34KB
- feed-20251208_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENVUE MEDICAL, INC. Date: December 12, 2025 By: /s/ Doron Besser Name: Doron Besser, M.D. Title: Chief Executive Officer